Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Vascular Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Weiss, T.
Right arrow Articles by Diehm, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, T.
Right arrow Articles by Diehm, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1

Thomas Weiss

Department of Cardiology/Angiology, University of Heidelberg, Heidelberg, Germany

Henning Eckstein

Department of Vascular Surgery, University of Heidelberg, Heidelberg, Germany

Claus Weiss

Department of Cardiology/Angiology, University of Heidelberg, Heidelberg, Germany

Curt Diehm

Department of Cardiology/Angiology, University of Heidelberg, Heidelberg, Germany

The role of polymorph nuclear neutrophils (PMN) in limb ischemia and reperfusion has been recognized only in recent years. The present study aimed to investigate the systemic and local (in femoral venous blood) effects of intra-arterially or intravenously applied prostaglandin E1 (PGE1) on systemic and ischemia-induced local changes in neutrophil function. Thirty patients with intermittent claudication were randomly assigned to intra-arterial or intravenous infusion of prostaglandin E1 (10 mgIAor15 mg IV over 30 min). Prior to infusion femoral arterial and venous blood samples were obtained from the predominantly affected leg under resting conditions and immediately after a 3-min period of ischemia induced by suprasystolic thigh compression. After 24 h additional blood samples were obtained at baseline, following infusion of prostaglandin E1, and again after another 3-min period of ischemia following the prostaglandin E1 infusion.

Intra-arterially administered prostaglandin E1 caused an increase in the PMN count by 3.5 ± 2% (p,0.05) and a decrease in free oxygen radical production by 13 ± 8% (p,0.05) measured by whole blood chemiluminescence. Additionally, a trend for lower PMN filterabilities (9 ± 12%, NS) was observed. Intra-arterially infused prostaglandin E1 significantly reduced the ischemia-induced decrease in neutrophil filterability (arterial and venous blood difference after ischemia - control: 22 ± 17% (p,0.05); IA PGE1:8 ± 11% (NS), each compared to baseline). Intravenously administered prostaglandin E1 showed similar systemic effects as the intra-arterial application, but did not affect the ischemia-induced changes in neutrophil filterability. In conclusion, prostaglandin E1 reduces PMN activation in patients with peripheral arterial occlusive disease.

Key Words: neutrophil function • peripheral arterial occlusive disease • prostaglandin E1 • reactive oxygen metabolites

Vascular Medicine, Vol. 3, No. 3, 171-175 (1998)
DOI: 10.1177/1358836X9800300301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?